The family of GLP-1 receptor agonist drugs, widely known for their effectiveness in treating obesity and diabetes, is facing renewed scrutiny regarding potential ocular safety concerns. Recent research published this week in the British Journal of Ophthalmology indicates that Wegovy, the semaglutide formulation specifically authorized for weight loss at higher doses, demonstrates a significantly greater association with ischemic optic neuropathy (ION) – a form of “eye stroke” that can cause sudden vision loss – than other similar medications, such as Ozempic or Rybelsus, all manufactured by Novo Nordisk.
Researchers analyzed data from the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) between 2017 and 2024. After screening over 30 million reports, scientists identified that, although these events are rare, the risk of developing this visual impairment is nearly five times higher in Wegovy users compared to those using Ozempic. The study also revealed a marked gender difference: men are approximately three times more likely to develop this side effect than women.
Ischemic optic neuropathy occurs when blood flow to the optic nerve is abruptly interrupted. The study authors suggest the increased incidence may be linked to the potency and speed of administration of the injectable formulation for obesity. “The use of Wegovy at higher doses likely drives this stronger association by predisposing to optic nerve hypoperfusion through intravascular volume contraction and hypotension, although a direct clinical link has not yet been established,” the researchers explain.
This hypothesis is supported by the fact that Rybelsus, the semaglutide version administered in slow-release pills, showed no reported cases of ION in the analysis. Scientists emphasize this is the first study providing evidence of a neuropathy risk dependent on formulation and dosage, placing Wegovy at the highest level of suspicion. “These findings highlight a potential dose-related safety concern that requires urgent prospective evaluation to guide prescribing policies,” the research team concludes.
Wegovy and Ischemic Optic Neuropathy: What the Data Shows
The research, based on analysis of the FDA’s FAERS database, identified a statistically significant increase in reported cases of ION among Wegovy users. While the absolute risk remains low, the data suggests a heightened vigilance is warranted. According to the study, the risk of ION with Wegovy was almost five times greater than with Ozempic. The Spanish Agency of Medicines and Medical Products (AEMPS) previously confirmed a risk of ischemic optic neuropathy in patients treated with semaglutide in June 2025.
Independent experts, ophthalmologists from the University of Southampton who authored a commentary accompanying the research, warn that the growing popularity of these drugs makes clarifying these risks a priority. With rising obesity rates globally and the recent expansion of these treatments to children as young as 12, these ophthalmologists urge close monitoring.
These findings add to a growing body of medical literature reporting ocular complications associated with obesity medications, necessitating increased scrutiny from specialists. Despite the demonstrated benefits of these medications in areas such as dementia and cardiovascular disease, the study reminds us that rapid weight loss and associated hemodynamic changes could have unforeseen consequences for the visual health of some patients.
Understanding Ischemic Optic Neuropathy
Ischemic optic neuropathy (ION) is a condition characterized by damage to the optic nerve due to insufficient blood supply. Symptoms typically include sudden, painless vision loss in one eye. The American Academy of Ophthalmology explains that ION can lead to permanent vision loss if not promptly diagnosed and addressed. While the exact cause of ION is often unclear, risk factors include high blood pressure, diabetes, and certain medications.
The researchers suggest that the rapid changes in blood volume and blood pressure associated with Wegovy’s higher dosage may contribute to the increased risk of ION. Further research is needed to fully understand the underlying mechanisms and identify individuals who may be more susceptible to this adverse effect.
What Should Patients Do?
Patients taking Wegovy or Ozempic who experience sudden vision loss or changes in vision should immediately seek medical attention from an ophthalmologist. While the risk of ION is low, early diagnosis and treatment are crucial to minimizing potential vision loss. Healthcare providers should also be aware of this potential side effect and discuss the risks and benefits of these medications with their patients.
The findings underscore the importance of ongoing monitoring and research into the long-term safety of GLP-1 receptor agonists. As these medications continue to gain popularity, a comprehensive understanding of their potential adverse effects is essential to ensure patient safety.
Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
What are your thoughts on this new research? Share your comments below, and please share this article with anyone who may locate it helpful.